|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
|
JPS5927900A
(ja)
|
1982-08-09 |
1984-02-14 |
Wakunaga Seiyaku Kk |
固定化オリゴヌクレオチド
|
|
US4501729A
(en)
|
1982-12-13 |
1985-02-26 |
Research Corporation |
Aerosolized amiloride treatment of retained pulmonary secretions
|
|
FR2540122B1
(fr)
|
1983-01-27 |
1985-11-29 |
Centre Nat Rech Scient |
Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
|
|
US4605735A
(en)
|
1983-02-14 |
1986-08-12 |
Wakunaga Seiyaku Kabushiki Kaisha |
Oligonucleotide derivatives
|
|
US4948882A
(en)
|
1983-02-22 |
1990-08-14 |
Syngene, Inc. |
Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
|
|
US4824941A
(en)
|
1983-03-10 |
1989-04-25 |
Julian Gordon |
Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
|
|
US4587044A
(en)
|
1983-09-01 |
1986-05-06 |
The Johns Hopkins University |
Linkage of proteins to nucleic acids
|
|
US5118802A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
|
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
US5430136A
(en)
|
1984-10-16 |
1995-07-04 |
Chiron Corporation |
Oligonucleotides having selectably cleavable and/or abasic sites
|
|
US5258506A
(en)
|
1984-10-16 |
1993-11-02 |
Chiron Corporation |
Photolabile reagents for incorporation into oligonucleotide chains
|
|
US4828979A
(en)
|
1984-11-08 |
1989-05-09 |
Life Technologies, Inc. |
Nucleotide analogs for nucleic acid labeling and detection
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5405938A
(en)
|
1989-12-20 |
1995-04-11 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US4762779A
(en)
|
1985-06-13 |
1988-08-09 |
Amgen Inc. |
Compositions and methods for functionalizing nucleic acids
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
US5317098A
(en)
|
1986-03-17 |
1994-05-31 |
Hiroaki Shizuya |
Non-radioisotope tagging of fragments
|
|
JPS638396A
(ja)
|
1986-06-30 |
1988-01-14 |
Wakunaga Pharmaceut Co Ltd |
ポリ標識化オリゴヌクレオチド誘導体
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
AU598946B2
(en)
|
1987-06-24 |
1990-07-05 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
|
WO1989005358A1
(en)
|
1987-11-30 |
1989-06-15 |
University Of Iowa Research Foundation |
Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
|
|
US5082830A
(en)
|
1988-02-26 |
1992-01-21 |
Enzo Biochem, Inc. |
End labeled nucleotide probe
|
|
WO1989009221A1
(en)
|
1988-03-25 |
1989-10-05 |
University Of Virginia Alumni Patents Foundation |
Oligonucleotide n-alkylphosphoramidates
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5109124A
(en)
|
1988-06-01 |
1992-04-28 |
Biogen, Inc. |
Nucleic acid probe linked to a label having a terminal cysteine
|
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5262536A
(en)
|
1988-09-15 |
1993-11-16 |
E. I. Du Pont De Nemours And Company |
Reagents for the preparation of 5'-tagged oligonucleotides
|
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
|
US5457183A
(en)
|
1989-03-06 |
1995-10-10 |
Board Of Regents, The University Of Texas System |
Hydroxylated texaphyrins
|
|
US5599923A
(en)
|
1989-03-06 |
1997-02-04 |
Board Of Regents, University Of Tx |
Texaphyrin metal complexes having improved functionalization
|
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5451463A
(en)
|
1989-08-28 |
1995-09-19 |
Clontech Laboratories, Inc. |
Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5254469A
(en)
|
1989-09-12 |
1993-10-19 |
Eastman Kodak Company |
Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5292873A
(en)
|
1989-11-29 |
1994-03-08 |
The Research Foundation Of State University Of New York |
Nucleic acids labeled with naphthoquinone probe
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
|
WO1991013080A1
(en)
|
1990-02-20 |
1991-09-05 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
ES2116977T3
(es)
|
1990-05-11 |
1998-08-01 |
Microprobe Corp |
Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
|
|
GB9011454D0
(en)
*
|
1990-05-22 |
1990-07-11 |
Medical Res Council |
Polynucleotide amplification
|
|
JPH06500688A
(ja)
|
1990-06-29 |
1994-01-27 |
ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン |
神経線維腫遺伝子
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
BR9106702A
(pt)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals Inc |
Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
|
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US5245022A
(en)
|
1990-08-03 |
1993-09-14 |
Sterling Drug, Inc. |
Exonuclease resistant terminally substituted oligonucleotides
|
|
NZ239247A
(en)
|
1990-08-03 |
1993-11-25 |
Sterling Drug Inc |
Oligonucleosides containing a non-phosphate inter nucleoside linkage
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
WO1992005186A1
(en)
|
1990-09-20 |
1992-04-02 |
Gilead Sciences |
Modified internucleoside linkages
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
EP0556301B1
(en)
|
1990-11-08 |
2001-01-10 |
Hybridon, Inc. |
Incorporation of multiple reporter groups on synthetic oligonucleotides
|
|
US5510473A
(en)
|
1990-11-09 |
1996-04-23 |
The United States Of American As Represented By The Secretary Of Health And Human Services |
Cloning of the recA gene from thermus aquaticus YT-1
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
US5371241A
(en)
|
1991-07-19 |
1994-12-06 |
Pharmacia P-L Biochemicals Inc. |
Fluorescein labelled phosphoramidites
|
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
|
EP0724447B1
(en)
|
1991-10-24 |
2003-05-07 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
US5565552A
(en)
|
1992-01-21 |
1996-10-15 |
Pharmacyclics, Inc. |
Method of expanded porphyrin-oligonucleotide conjugate synthesis
|
|
US5595726A
(en)
|
1992-01-21 |
1997-01-21 |
Pharmacyclics, Inc. |
Chromophore probe for detection of nucleic acid
|
|
GB9206016D0
(en)
|
1992-03-19 |
1992-04-29 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5434257A
(en)
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
|
WO1993025673A1
(en)
|
1992-06-04 |
1993-12-23 |
The Regents Of The University Of California |
In vivo gene therapy with intron-free sequence of interest
|
|
US5272250A
(en)
|
1992-07-10 |
1993-12-21 |
Spielvogel Bernard F |
Boronated phosphoramidate compounds
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
EP0681483B1
(en)
|
1993-01-26 |
2005-08-24 |
The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) |
Compositions and methods for delivery of genetic material
|
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
DE69407032T2
(de)
|
1993-03-31 |
1998-07-02 |
Sanofi Sa |
Oligonucleotide mit amidverkettungen die phosphoesterverkettungen einsetzen
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
PT733059E
(pt)
|
1993-12-09 |
2001-03-30 |
Univ Jefferson |
Compostos e metodos para mutacoes dirigidas ao local em celulas eucarioticas
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
US5597696A
(en)
|
1994-07-18 |
1997-01-28 |
Becton Dickinson And Company |
Covalent cyanine dye oligonucleotide conjugates
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
US5962428A
(en)
|
1995-03-30 |
1999-10-05 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
CA2263784A1
(en)
|
1998-03-23 |
1999-09-23 |
Megabios Corporation |
Dual-tagged proteins and their uses
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
CA2348382C
(en)
|
1998-11-10 |
2013-09-17 |
The University Of North Carolina At Chapel Hill |
Chimeric parvovirus vectors and methods of making and administering the same
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
ATE356824T1
(de)
|
1999-05-04 |
2007-04-15 |
Santaris Pharma As |
L-ribo-lna analoge
|
|
US20040192593A1
(en)
|
1999-07-26 |
2004-09-30 |
Baylor College Of Medicine |
Protease resistant ti-growth hormone releasing hormone
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
WO2001083783A2
(en)
|
2000-04-28 |
2001-11-08 |
Genzyme Corporation |
In vivo loading of mhc
|
|
AU2001253914B2
(en)
|
2000-04-28 |
2006-06-08 |
Sangamo Therapeutics, Inc. |
Targeted modification of chromatin structure
|
|
ES2256265T3
(es)
|
2000-06-01 |
2006-07-16 |
University Of North Carolina At Chapel Hill |
Vectores de parvovirus duplicados.
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
US7879540B1
(en)
|
2000-08-24 |
2011-02-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
|
WO2003016496A2
(en)
|
2001-08-20 |
2003-02-27 |
The Scripps Research Institute |
Zinc finger binding domains for cnn
|
|
WO2003020739A2
(en)
|
2001-09-04 |
2003-03-13 |
Exiqon A/S |
Novel lna compositions and uses thereof
|
|
AU2003219847A1
(en)
|
2002-02-21 |
2003-09-09 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for reversibly controlling expression of target genes in cells
|
|
US7449561B1
(en)
|
2002-02-26 |
2008-11-11 |
City Of Hope |
Alterations in the dystrophin gene associated with sporadic dilated cardiomyopathy
|
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
|
WO2004002453A1
(en)
|
2002-06-28 |
2004-01-08 |
Protiva Biotherapeutics Ltd. |
Method and apparatus for producing liposomes
|
|
EP1573004A4
(en)
|
2002-11-04 |
2006-08-09 |
Advisys Inc |
SYNTHETIC MUSCLE PROMOTERS WITH INHERENT CELLS NATURALLY OBTAINING REGULATORY SEQUENCES EXCELLENT ACTIVITIES
|
|
AU2004263884A1
(en)
|
2003-08-08 |
2005-02-17 |
President And Fellows Of Harvard College |
SiRNA based methods for treating Alzheimer's disease
|
|
CA2539439C
(en)
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
US20070192880A1
(en)
|
2003-10-03 |
2007-08-16 |
University Of Rochester |
Horming response element binding transregulators
|
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
|
AU2005251403B2
(en)
|
2004-06-07 |
2011-09-01 |
Arbutus Biopharma Corporation |
Cationic lipids and methods of use
|
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
US7728118B2
(en)
|
2004-09-17 |
2010-06-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
|
WO2007012191A1
(en)
|
2005-07-27 |
2007-02-01 |
Protiva Biotherapeutics, Inc. |
Systems and methods for manufacturing liposomes
|
|
WO2007019301A2
(en)
|
2005-08-05 |
2007-02-15 |
Michigan State University |
Genes from actinobacillus succinogenes 13oz (atcc 55618) for production of chemicals from the a. succinogenes c4-pathway
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
LT2578685T
(lt)
|
2005-08-23 |
2019-06-10 |
The Trustees Of The University Of Pennsylvania |
Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
|
|
AU2007269048A1
(en)
|
2006-07-05 |
2008-01-10 |
The Scripps Research Institute |
Chimeric zinc finger recombinases optimized for catalysis by directed evolution
|
|
WO2008073303A2
(en)
|
2006-12-07 |
2008-06-19 |
Switchgear Genomics |
Transcriptional regulatory elements of biological pathways, tools, and methods
|
|
WO2008070859A2
(en)
|
2006-12-07 |
2008-06-12 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Treatment of skin conditions by dickkopf1 (dkk1)
|
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
|
WO2008151631A2
(en)
|
2007-06-15 |
2008-12-18 |
Exiqon A/S |
Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
US20100076057A1
(en)
|
2008-09-23 |
2010-03-25 |
Northwestern University |
TARGET DNA INTERFERENCE WITH crRNA
|
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
BRPI0914440A8
(pt)
|
2008-10-17 |
2016-01-19 |
Joule Unlimited Inc |
Método para produção biogênica de etanol e cianobactéria geneticamente modificada
|
|
DK3133160T3
(en)
|
2008-10-24 |
2019-04-01 |
Sarepta Therapeutics Inc |
EXON SKIP COMPOSITIONS FOR DMD
|
|
WO2010075424A2
(en)
|
2008-12-22 |
2010-07-01 |
The Regents Of University Of California |
Compositions and methods for downregulating prokaryotic genes
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
US20120207744A1
(en)
|
2009-03-19 |
2012-08-16 |
Mendlein John D |
Reprogramming compositions and methods of using the same
|
|
SG10201912450XA
(en)
|
2009-06-10 |
2020-03-30 |
Arbutus Biopharma Corp |
Improved lipid formulation
|
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
|
EP2480659A2
(en)
|
2009-09-24 |
2012-08-01 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
BR112012009921B1
(pt)
|
2009-10-31 |
2021-06-29 |
New World Laboratories Inc |
Metodo para obter uma célula tronco neural
|
|
US8586363B2
(en)
|
2009-12-10 |
2013-11-19 |
Regents Of The University Of Minnesota |
TAL effector-mediated DNA modification
|
|
EP2533629B1
(en)
|
2010-02-11 |
2018-11-28 |
Recombinetics, Inc. |
Methods and materials for producing transgenic artiodactyls
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
EP2517731A1
(en)
|
2011-04-07 |
2012-10-31 |
Ludwig-Maximilians-Universität München |
Method of activating a target gene in a cell
|
|
EP2729567B1
(en)
|
2011-07-08 |
2016-10-05 |
Cellectis |
Method for increasing the efficiency of double-strand break-induced mutagenssis
|
|
CA2854819C
(en)
|
2011-11-16 |
2022-07-19 |
Sangamo Biosciences, Inc. |
Modified dna-binding proteins and uses thereof
|
|
US8450107B1
(en)
|
2011-11-30 |
2013-05-28 |
The Broad Institute Inc. |
Nucleotide-specific recognition sequences for designer TAL effectors
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
JP2015509922A
(ja)
|
2012-01-27 |
2015-04-02 |
プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． |
デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド
|
|
US20130274129A1
(en)
|
2012-04-04 |
2013-10-17 |
Geneart Ag |
Tal-effector assembly platform, customized services, kits and assays
|
|
US9738879B2
(en)
|
2012-04-27 |
2017-08-22 |
Duke University |
Genetic correction of mutated genes
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
WO2013176772A1
(en)
|
2012-05-25 |
2013-11-28 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
PL3494997T3
(pl)
|
2012-07-25 |
2020-04-30 |
The Broad Institute, Inc. |
Indukowalne białka wiążące dna i narzędzia perturbacji genomu oraz ich zastosowania
|
|
WO2014025887A1
(en)
|
2012-08-07 |
2014-02-13 |
The General Hospital Corporation |
Selective reactivation of genes on the inactive x chromosome
|
|
EP2906602B1
(en)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
KR101656236B1
(ko)
|
2012-10-23 |
2016-09-12 |
주식회사 툴젠 |
표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
|
|
WO2014071219A1
(en)
|
2012-11-01 |
2014-05-08 |
Factor Bioscience Inc. |
Methods and products for expressing proteins in cells
|
|
US20140140969A1
(en)
|
2012-11-20 |
2014-05-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for muscular dystrophies
|
|
ES2713243T3
(es)
|
2012-12-06 |
2019-05-20 |
Sigma Aldrich Co Llc |
Modificación y regulación del genoma basada en CRISPR
|
|
WO2014093479A1
(en)
|
2012-12-11 |
2014-06-19 |
Montana State University |
Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
|
|
AU2013359199C1
(en)
|
2012-12-12 |
2021-06-17 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
ES2701749T3
(es)
|
2012-12-12 |
2019-02-25 |
Broad Inst Inc |
Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
|
|
EP4234696A3
(en)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
IL307735A
(en)
|
2012-12-12 |
2023-12-01 |
Broad Inst Inc |
Systems engineering, methods and optimal guiding components for sequence manipulation
|
|
EP4481048A3
(en)
|
2012-12-17 |
2025-02-26 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
|
AU2014228981B2
(en)
|
2013-03-15 |
2019-11-28 |
The General Hospital Corporation |
Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
|
|
BR112015022998A2
(pt)
*
|
2013-03-15 |
2017-11-14 |
Sarepta Therapeutics Inc |
composições melhoradas para o tratamento de distrofia muscular
|
|
CA2906869C
(en)
|
2013-03-15 |
2022-08-02 |
Edward J. Britt |
Energy conversion device and method for making and using same
|
|
WO2014186585A2
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
KR102884236B1
(ko)
|
2013-06-04 |
2025-11-12 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Rna-가이드된 전사 조절
|
|
ES2991293T3
(es)
|
2013-06-05 |
2024-12-03 |
Univ Duke |
Edición génica guiada por ARN y regulación génica
|
|
SG11201510284XA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
|
CA2915845A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
WO2014204723A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
|
|
SMT202100691T1
(it)
|
2013-07-11 |
2022-01-10 |
Modernatx Inc |
Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
|
|
US10421957B2
(en)
|
2013-07-29 |
2019-09-24 |
Agilent Technologies, Inc. |
DNA assembly using an RNA-programmable nickase
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US20150044772A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
Crispr/cas system-based novel fusion protein and its applications in genome editing
|
|
CN105492598B
(zh)
|
2013-08-29 |
2019-12-03 |
三浦典正 |
与细胞的抗衰老相关的生物分子群
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US10822606B2
(en)
|
2013-09-27 |
2020-11-03 |
The Regents Of The University Of California |
Optimized small guide RNAs and methods of use
|
|
EP4372090A3
(en)
|
2013-11-07 |
2024-08-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions with governing grnas
|
|
KR20160097327A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
|
|
AU2014362245A1
(en)
|
2013-12-12 |
2016-06-16 |
Massachusetts Institute Of Technology |
Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
|
|
KR20250068794A
(ko)
|
2013-12-12 |
2025-05-16 |
더 브로드 인스티튜트, 인코퍼레이티드 |
게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
|
|
WO2015114059A1
(en)
|
2014-01-29 |
2015-08-06 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Trans-differentiation of differentiated cells
|
|
DK3116997T3
(da)
|
2014-03-10 |
2019-08-19 |
Editas Medicine Inc |
Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10)
|
|
EP3129490A4
(en)
|
2014-04-08 |
2017-10-04 |
North Carolina State University |
Methods and compositions for rna-directed repression of transcription using crispr-associated genes
|
|
KR20250102123A
(ko)
|
2014-04-18 |
2025-07-04 |
에디타스 메디신, 인코포레이티드 |
암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
|
|
CA2952697A1
(en)
|
2014-06-16 |
2015-12-23 |
The Johns Hopkins University |
Compositions and methods for the expression of crispr guide rnas using the h1 promoter
|
|
CA2954791C
(en)
|
2014-07-14 |
2025-11-18 |
The Regents Of The Univ Of California |
Crispr/cas transcriptional modulation
|
|
US20170219596A1
(en)
|
2014-07-14 |
2017-08-03 |
The Regents Of The University Of California |
A protein tagging system for in vivo single molecule imaging and control of gene transcription
|
|
US9932566B2
(en)
|
2014-08-07 |
2018-04-03 |
Agilent Technologies, Inc. |
CIS-blocked guide RNA
|
|
CN106714845A
(zh)
|
2014-08-11 |
2017-05-24 |
得克萨斯州大学系统董事会 |
通过crispr/cas9介导的基因编辑预防肌营养不良
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
MA40880A
(fr)
|
2014-10-30 |
2017-09-05 |
Temple Univ Of The Commonwealth |
Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus
|
|
WO2016081924A1
(en)
|
2014-11-20 |
2016-05-26 |
Duke University |
Compositions, systems and methods for cell therapy
|
|
BR112017010547A2
(pt)
|
2014-11-21 |
2018-02-27 |
Regeneron Pharma |
métodos para produção de uma modificação bialélica, modificação de um genoma dentro de uma célula, produção de uma geração f0 de um animal não humano e identificação de uma inserção de um inserto de ácido nucleico.
|
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
US10190106B2
(en)
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
|
EP3245232B1
(en)
|
2015-01-12 |
2021-04-21 |
The Regents of The University of California |
Heterodimeric cas9 and methods of use thereof
|
|
WO2016123578A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
|
US20160281166A1
(en)
|
2015-03-23 |
2016-09-29 |
Parabase Genomics, Inc. |
Methods and systems for screening diseases in subjects
|
|
WO2016161380A1
(en)
*
|
2015-04-01 |
2016-10-06 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
|
|
WO2016170348A2
(en)
|
2015-04-22 |
2016-10-27 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
|
KR102535217B1
(ko)
|
2015-04-24 |
2023-05-19 |
에디타스 메디신, 인코포레이티드 |
Ｃａｓ9 분자/가이드 ｒｎａ 분자 복합체의 평가
|
|
WO2016187717A1
(en)
|
2015-05-26 |
2016-12-01 |
Exerkine Corporation |
Exosomes useful for genome editing
|
|
MX392008B
(es)
|
2015-06-18 |
2025-03-21 |
Broad Inst Inc |
Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
US11064697B2
(en)
|
2015-07-24 |
2021-07-20 |
Basf Se |
Pyridine compounds useful for combating phytopathogenic fungi
|
|
US20200123533A1
(en)
|
2015-07-31 |
2020-04-23 |
The Trustees Of Columbia University In The City Of New York |
High-throughput strategy for dissecting mammalian genetic interactions
|
|
JP6905755B2
(ja)
|
2015-08-25 |
2021-07-21 |
デューク ユニバーシティ |
Ｒｎａガイド型エンドヌクレアーゼを使用してゲノム工学における特異性を改善する組成物および方法
|
|
CA2998894A1
(en)
|
2015-09-18 |
2017-03-23 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
|
US20180265859A1
(en)
|
2015-09-23 |
2018-09-20 |
UNIVERSITé LAVAL |
Modification of the dystrophin gene and uses thereof
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
IL294014B2
(en)
|
2015-10-23 |
2024-07-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
EP4279084B1
(en)
|
2015-10-28 |
2025-06-11 |
Vertex Pharmaceuticals Inc. |
Materials and methods for treatment of duchenne muscular dystrophy
|
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
|
US11566052B2
(en)
|
2015-11-11 |
2023-01-31 |
Lonza Ltd. |
CRISPR-associated (Cas) proteins with reduced immunogenicity
|
|
US11306308B2
(en)
|
2015-11-13 |
2022-04-19 |
Massachusetts Institute Of Technology |
High-throughput CRISPR-based library screening
|
|
EA201891317A3
(ru)
|
2015-11-30 |
2019-04-30 |
Дьюк Юниверсити |
Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
|
|
BR112018013679A2
(pt)
|
2016-01-11 |
2019-01-22 |
Univ Leland Stanford Junior |
proteínas quiméricas e métodos de regulação de expressão gênica
|
|
EP3199632A1
(en)
|
2016-01-26 |
2017-08-02 |
ACIB GmbH |
Temperature-inducible crispr/cas system
|
|
WO2017139505A2
(en)
|
2016-02-11 |
2017-08-17 |
The Regents Of The University Of California |
Methods and compositions for modifying a mutant dystrophin gene in a cell's genome
|
|
WO2017165859A1
(en)
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
MX391208B
(es)
|
2016-04-15 |
2025-03-21 |
Res Inst Nationwide Childrens Hospital |
Vectores del virus adenoasociado de b-sarcoglicano y microarn-29 y el uso de los mismos en la distrofia muscular.
|
|
CN109661470A
(zh)
|
2016-04-15 |
2019-04-19 |
宾夕法尼亚州大学信托人 |
新型aav8突变衣壳和含有其的组合物
|
|
WO2017193029A2
(en)
*
|
2016-05-05 |
2017-11-09 |
Duke University |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy
|
|
WO2017201199A1
(en)
|
2016-05-17 |
2017-11-23 |
Duke University |
Compositions and methods for the treatment of prader-willi syndrome
|
|
US20170362635A1
(en)
|
2016-06-20 |
2017-12-21 |
University Of Washington |
Muscle-specific crispr/cas9 editing of genes
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
TW201811807A
(zh)
|
2016-06-30 |
2018-04-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
JP2019524098A
(ja)
|
2016-07-15 |
2019-09-05 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
非分裂細胞のゲノム編集のための方法と組成物
|
|
AU2017300272A1
(en)
|
2016-07-18 |
2019-01-31 |
Jaan Biotherapeutics, Llc |
Compositions and methods for treatment of cardiac diseases
|
|
WO2018017751A1
(en)
|
2016-07-19 |
2018-01-25 |
Supereye, Inc. |
Systems and methods for predictive visual rendering
|
|
US12214056B2
(en)
|
2016-07-19 |
2025-02-04 |
Duke University |
Therapeutic applications of CPF1-based genome editing
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
CN110114461A
(zh)
|
2016-08-17 |
2019-08-09 |
博德研究所 |
新型crispr酶和系统
|
|
SG11201901306XA
(en)
|
2016-08-19 |
2019-03-28 |
Toolgen Inc |
Artificially engineered angiogenesis regulatory system
|
|
US11434476B2
(en)
|
2016-08-19 |
2022-09-06 |
Whitehead Institute For Biomedical Research |
Methods of editing DNA methylation
|
|
KR102594051B1
(ko)
|
2016-08-20 |
2023-10-26 |
아벨리노 랩 유에스에이, 인크. |
단일 가이드 RNA, CRISPR/Cas9 시스템, 및 이의 사용방법
|
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
|
WO2018081504A1
(en)
|
2016-10-28 |
2018-05-03 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus
|
|
WO2018098480A1
(en)
|
2016-11-28 |
2018-05-31 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
|
|
US20200056206A1
(en)
|
2016-12-01 |
2020-02-20 |
UNIVERSITé LAVAL |
Crispr-based treatment of friedreich ataxia
|
|
CA3046220A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
JP2018143239A
(ja)
|
2017-03-01 |
2018-09-20 |
エリクサジェン，エルエルシー． |
多能性幹細胞を所望の細胞型へ効率的に分化する方法
|
|
US20210322577A1
(en)
|
2017-03-03 |
2021-10-21 |
Flagship Pioneering Innovations V, Inc. |
Methods and systems for modifying dna
|
|
US10687520B2
(en)
|
2017-03-07 |
2020-06-23 |
The Board Of Regents Of The University Of Texas System |
Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44
|
|
WO2018162702A1
(en)
|
2017-03-10 |
2018-09-13 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Nuclease fusions for enhancing genome editing by homology-directed transgene integration
|
|
US11541130B2
(en)
|
2017-03-23 |
2023-01-03 |
DNARx |
Systems and methods for nucleic acid expression in vivo
|
|
AU2017407272B2
(en)
|
2017-03-30 |
2024-06-13 |
Kyoto University |
Method for inducing exon skipping by genome editing
|
|
CA3059757A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Novel type vi crispr orthologs and systems
|
|
US20180305719A1
(en)
|
2017-04-19 |
2018-10-25 |
The Board Of Trustees Of The University Of Illinois |
Vectors For Integration Of DNA Into Genomes And Methods For Altering Gene Expression And Interrogating Gene Function
|
|
WO2018208998A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
|
EP3420811A1
(en)
|
2017-06-29 |
2019-01-02 |
Paris Sciences et Lettres - Quartier Latin |
Non-human model for neurofibromatosis type 1
|
|
KR102691097B1
(ko)
|
2017-07-07 |
2024-08-02 |
주식회사 툴젠 |
표적 특이적 crispr 변이체
|
|
WO2019014122A1
(en)
|
2017-07-08 |
2019-01-17 |
The Brigham And Women's Hospital, Inc. |
METHODS FOR ENHANCING ANTIANGIOGENIC THERAPY AND IMMUNOTHERAPY
|
|
US20210355508A1
(en)
|
2017-07-25 |
2021-11-18 |
Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences |
Method for Modulating RNA Splicing by Inducing Base Mutation at Splice Site or Base Substitution in Polypyrimidine Region
|
|
WO2019023291A2
(en)
|
2017-07-25 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR PRODUCTION AND DECODING OF GUIDE RNA LIBRARIES AND USES THEREOF
|
|
EP3441461A1
(en)
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
US20200260698A1
(en)
|
2017-08-18 |
2020-08-20 |
The Board Of Regents Of The University Of Texas System |
Exon deletion correction of duchenne muscular dystrophy mutations in the dystrophin actin binding domain 1 using crispr genome editing
|
|
AU2018326780A1
(en)
|
2017-08-31 |
2020-02-27 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
US11779653B2
(en)
|
2017-09-29 |
2023-10-10 |
The Regents Of The University Of California |
Multi-armed polyrotaxane platform for protected nucleic acid delivery
|
|
WO2019079514A1
(en)
|
2017-10-17 |
2019-04-25 |
Massachusetts Institute Of Technology |
METHODS OF FUNCTIONAL DISSECTION AT THE GENOME SCALE AT HIGH RESOLUTION OF TRANSCRIPTIONAL REGULATORY REGIONS
|
|
BR112020004351A2
(pt)
|
2017-10-19 |
2020-09-08 |
Curevac Ag |
moléculas de ácido nucleico artificial
|
|
US20210268667A1
(en)
|
2017-10-23 |
2021-09-02 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
|
|
WO2019092505A1
(en)
|
2017-11-09 |
2019-05-16 |
Casebia Therapeutics Llp |
Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
|
|
JP2021505200A
(ja)
|
2017-12-08 |
2021-02-18 |
ユニヴァーシティ オブ コネチカット |
ゲノムインプリンティングの障害を治療するための組成物及び方法
|
|
SG11202005609PA
(en)
|
2017-12-15 |
2020-07-29 |
Univ Leland Stanford Junior |
Compositions and methods for inhibiting t cell exhaustion
|
|
US11293019B2
(en)
|
2017-12-22 |
2022-04-05 |
Gflas Life Sciences, Inc. |
Chimeric genome engineering molecules and methods
|
|
WO2019131829A1
(ja)
|
2017-12-28 |
2019-07-04 |
国立大学法人京都大学 |
標的遺伝子改変用組成物
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
US20220010293A1
(en)
|
2018-02-23 |
2022-01-13 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 orthologs
|
|
US20210254049A1
(en)
|
2018-04-20 |
2021-08-19 |
Cellino Biotech, Inc. |
Directed cell fate specification and targeted maturation
|
|
WO2019213626A1
(en)
|
2018-05-03 |
2019-11-07 |
President And Fellows Of Harvard College |
In vivo homology directed repair in heart, skeletal muscle, and muscle stem cells
|
|
CA3101477A1
(en)
|
2018-05-30 |
2019-12-05 |
M2X2 Therapeutics, Inc. |
Cell therapy
|
|
WO2020018918A1
(en)
|
2018-07-19 |
2020-01-23 |
The Board Of Trustees Of The University Of Illinois |
Methods for exon skipping and gene knockout using base editors
|
|
US20220118109A1
(en)
|
2018-12-20 |
2022-04-21 |
Ohio State Innovation Foundation |
Compositions and methods for reprogramming diseased musculoskeletal cells
|
|
BR102019009665A2
(pt)
|
2018-12-21 |
2022-02-08 |
Jacques P. Tremblay |
Modificação da proteína precursora beta amiloide (app) através da edição de base usando o sistema crispr/cas9
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
CA3128755C
(en)
|
2019-02-13 |
2024-06-04 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
|
EP3952884A4
(en)
|
2019-04-12 |
2023-03-22 |
Duke University |
Crispr/cas-based base editing composition for restoring dystrophin function
|
|
JP2022529424A
(ja)
|
2019-04-14 |
2022-06-22 |
デューク ユニバーシティ |
ジストロフィン機能を修復するためのＣＲＩＳＰＲ／Ｃａｓをベースにしたゲノム編集組成物
|
|
AR118670A1
(es)
|
2019-04-14 |
2021-10-20 |
Univ Duke |
Eliminación mediada por vectores aav de grandes puntos de mutación para el tratamiento de la distrofia muscular de duchenne
|
|
AU2020297596A1
(en)
|
2019-06-20 |
2022-02-03 |
Celgene Corporation |
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
|
|
US20220396790A1
(en)
|
2019-08-08 |
2022-12-15 |
Duke University |
High-throughput screening platform for engineering next-generation gene therapy vectors
|
|
CN114599403A
(zh)
|
2019-08-19 |
2022-06-07 |
杜克大学 |
通过基于crispr/cas9的转录激活物获得的骨骼肌成肌细胞祖细胞谱系的特化
|
|
CA3151336A1
(en)
|
2019-08-19 |
2021-02-25 |
Duke University |
Compositions and methods for identifying regulators of cell type fate specification
|
|
EP4031147A4
(en)
|
2019-09-20 |
2024-10-02 |
The UAB Research Foundation |
Methods of treatment of neurofibromatosis type 1 (nf1) and nf1-mediated conditions and compositions for use in such methods
|
|
US20220364124A1
(en)
|
2019-10-02 |
2022-11-17 |
Duke University |
Epigenetic modulation of genomic targets to control expression of pws-associated genes
|
|
AR122347A1
(es)
|
2019-12-03 |
2022-09-07 |
Univ Duke |
Sistemas y métodos para la distribución de maquinaria de edición génica por nanopartículas lipídicas
|
|
EP4126224A4
(en)
|
2020-04-27 |
2024-07-03 |
Duke University |
HIGH-THROUGHPUT SCREENING METHODS TO DISCOVER OPTIMAL GRNA PAIRS FOR CRISPR-MEDIATED EXON DELETION
|
|
US20230201375A1
(en)
|
2020-04-27 |
2023-06-29 |
Duke University |
Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1)
|
|
EP4125349A4
(en)
|
2020-04-27 |
2024-07-10 |
Duke University |
GENE EDITING OF SATELLITE CELLS IN VIVO USING AAV VECTORS ENCODING MUSCLE-SPECIFIC PROMOTERS
|
|
US20230303975A1
(en)
|
2020-08-21 |
2023-09-28 |
Julius-Maximilians-Universität Würzburg |
Modified lymphocytes
|
|
WO2022076901A1
(en)
|
2020-10-09 |
2022-04-14 |
Duke University |
Novel targets for reactivation of prader-willi syndrome-associated genes
|
|
US20230383270A1
(en)
|
2020-10-12 |
2023-11-30 |
Duke University |
Crispr/cas-based base editing composition for restoring dystrophin function
|
|
EP4232152A4
(en)
|
2020-10-21 |
2025-04-23 |
Duke University |
Dual AAV vector-mediated deletion of a large mutation hotspot for the treatment of Duchenne muscular dystrophy
|
|
IL302879A
(en)
|
2020-11-11 |
2023-07-01 |
Univ Columbia |
Multiplex epigenome editing
|
|
WO2022104159A1
(en)
|
2020-11-13 |
2022-05-19 |
Duke University |
Targeted gene regulation of human immune cells with crispr-cas systems
|
|
WO2022133062A1
(en)
|
2020-12-16 |
2022-06-23 |
Epicrispr Biotechnologies, Inc. |
Systems and methods for engineering characteristics of a cell
|
|
US20240141341A1
(en)
|
2021-03-01 |
2024-05-02 |
Duke University |
Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20250154503A1
(en)
|
2022-01-14 |
2025-05-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
US20240058425A1
(en)
|
2022-03-08 |
2024-02-22 |
Duke University |
Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
|
|
US20250262326A1
(en)
|
2022-04-13 |
2025-08-21 |
Duke University |
Effector domains for crispr-cas systems
|
|
CN119731321A
(zh)
|
2022-06-24 |
2025-03-28 |
图恩疗法股份有限公司 |
通过靶向基因阻遏减少低密度脂蛋白的组合物、系统和方法
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
WO2024040253A1
(en)
|
2022-08-18 |
2024-02-22 |
Duke University |
Epigenetic modulation of genomic targets to control expression of pws-associated genes
|
|
CA3264214A1
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics Inc |
Compositions, systems and methods of regulating the hepatitis B virus by targeted gene suppression
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
WO2024081937A2
(en)
|
2022-10-13 |
2024-04-18 |
Duke University |
Cas12a fusion proteins and methods of using same
|